LYEL Relative Valuation
LYEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LYEL is overvalued; if below, it's undervalued.
Historical Valuation
Lyell Immunopharma Inc (LYEL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.60. The fair price of Lyell Immunopharma Inc (LYEL) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：24.52
Fair
-2.72
PE
1Y
3Y
5Y
Trailing
Forward
-1.00
EV/EBITDA
Lyell Immunopharma Inc. (LYEL) has a current EV/EBITDA of -1.00. The 5-year average EV/EBITDA is -1.67. The thresholds are as follows: Strongly Undervalued below -9.21, Undervalued between -9.21 and -5.44, Fairly Valued between 2.10 and -5.44, Overvalued between 2.10 and 5.87, and Strongly Overvalued above 5.87. The current Forward EV/EBITDA of -1.00 falls within the Historic Trend Line -Fairly Valued range.
-0.96
EV/EBIT
Lyell Immunopharma Inc. (LYEL) has a current EV/EBIT of -0.96. The 5-year average EV/EBIT is -1.58. The thresholds are as follows: Strongly Undervalued below -8.56, Undervalued between -8.56 and -5.07, Fairly Valued between 1.91 and -5.07, Overvalued between 1.91 and 5.40, and Strongly Overvalued above 5.40. The current Forward EV/EBIT of -0.96 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Lyell Immunopharma Inc. (LYEL) has a current PS of 0.00. The 5-year average PS is 406.91. The thresholds are as follows: Strongly Undervalued below -2206.49, Undervalued between -2206.49 and -899.79, Fairly Valued between 1713.62 and -899.79, Overvalued between 1713.62 and 3020.32, and Strongly Overvalued above 3020.32. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Lyell Immunopharma Inc. (LYEL) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.81. The thresholds are as follows: Strongly Undervalued below -19.12, Undervalued between -19.12 and -12.96, Fairly Valued between -0.65 and -12.96, Overvalued between -0.65 and 5.50, and Strongly Overvalued above 5.50. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Lyell Immunopharma Inc. (LYEL) has a current P/FCF of 0.00. The 5-year average P/FCF is -6.27. The thresholds are as follows: Strongly Undervalued below -17.11, Undervalued between -17.11 and -11.69, Fairly Valued between -0.85 and -11.69, Overvalued between -0.85 and 4.57, and Strongly Overvalued above 4.57. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Lyell Immunopharma Inc (LYEL) has a current Price-to-Book (P/B) ratio of 1.31. Compared to its 3-year average P/B ratio of 0.71 , the current P/B ratio is approximately 84.48% higher. Relative to its 5-year average P/B ratio of 1.17, the current P/B ratio is about 11.52% higher. Lyell Immunopharma Inc (LYEL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -52.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -38.84% , the current FCF yield is about -100.00% lower.
1.49
P/B
Median3y
0.71
Median5y
1.17
-34.97
FCF Yield
Median3y
-52.68
Median5y
-38.84
Competitors Valuation Multiple
The average P/S ratio for LYEL's competitors is 0.00, providing a benchmark for relative valuation. Lyell Immunopharma Inc Corp (LYEL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -55.88%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LYEL increased by 98.91% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -131.13K to -258.97K.
The secondary factor is the P/E Change, contributed 57.29%to the performance.
Overall, the performance of LYEL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Lyell Immunopharma Inc (LYEL) currently overvalued or undervalued?
What is Lyell Immunopharma Inc (LYEL) fair value?
How does LYEL's valuation metrics compare to the industry average?
What is the current P/B ratio for Lyell Immunopharma Inc (LYEL) as of Dec 05 2025?
What is the current FCF Yield for Lyell Immunopharma Inc (LYEL) as of Dec 05 2025?
What is the current Forward P/E ratio for Lyell Immunopharma Inc (LYEL) as of Dec 05 2025?